Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Followup Data Backs Padcev-Keytruda Combo for 1st Line Bladder Cancer: Astellas/Seattle Genetics
February 13, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
- Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
February 10, 2020
- Chugai Joins NCC Scheme to Offer Free Drugs after Genomic Profiling
February 10, 2020
- After Erleada, Janssen Joins Hands with Nippon Shinyaku for Zytiga Too
February 10, 2020
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- I’rom Teams Up with Shanghai Public Health Clinical Center to Tackle Novel Coronavirus
February 10, 2020
- Novo Nordisk’s Fiasp Ultra-Fast Acting Insulin Now Available in Japan
February 10, 2020
- Japan Ethical Drug Sales Up 3.7% in December 2019: Crecon
February 10, 2020
- With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
- Keytruda’s Global Sales Cross US$10 Billion Mark in 2019, Tops Opdivo’s Including Asia
February 7, 2020
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Keytruda Stays Atop Encise’s January Drug Ranking
February 7, 2020
- Zeria Licenses Acofide to Spanish Pharma in 13 Latin American Countries
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Mitsubishi Tanabe’s April-December Sales Fall 10.5% as Gilenya Feud Continues
February 5, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…